Ifetroban

Unknown / undisclosed

Phase 2topline reported

Evidence outlook

Systemic Sclerosis: topline reported 2026-10-23

The sponsor reported topline results on 2026-10-23 (Phase 2 ASSIST-SSc pilot of ifetroban reports top-line safety results). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (10)
Systemic Sclerosis
Other / comorbidity
NCT03694249 · Vanderbilt-Ingram Cancer Center
2018-12-12 – 2026-04 · Malignant Solid Tumor
What this study did
NCT03340675 · Cumberland Pharmaceuticals
2020-10-19 – 2026-01-23 · Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
What this study did
NCT03326063 · Brigham and Women's Hospital
2018-04-26 – 2023-04-15 · Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
What this study did
NCT03962855 · Jeffrey Rade
2019-09-20 – 2022-11-15 · Cardiovascular Diseases, Vascular Dilation
What this study did
NCT02802228 · Cumberland Pharmaceuticals
2017-03-06 – 2018-07-17 · Portal Hypertension, Liver Cirrhosis
What this study did
NCT02216357 · Cumberland Pharmaceuticals
2014-08 – 2016-01 · Aspirin Exacerbated Respiratory Disease (AERD)
What this study did
NCT01436500 · Cumberland Pharmaceuticals
2011-10 – 2015-07 · Hepatorenal Syndrome
What this study did

Competitive landscape

This drug's own stage for Systemic Sclerosis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ifetroban: this drugPhase 2—Thromboxane A2 receptor (TP receptor)not yet gradedNo reviewed efficacy summary in this indication
Nintedanib (Ofev)ApprovedSmall moleculeTriple angiokinase inhibitor (VEGFR/FGFR/PDGFR)not yet gradedNo reviewed efficacy summary in this indication
AnifrolumabPhase 3Monoclonal antibodyType I interferon receptor subunit 1 (IFNAR1)not yet gradedNo reviewed efficacy summary in this indication
Bosentan (Tracleer)Phase 3Small moleculeEndothelin receptor (ETA/ETB, dual)not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Nerandomilast (Jascayd)Phase 3Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Yutrepia, Liquidia)Phase 2Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ifetroban to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Phase 2Idiopathic Pulmonary FibrosisRecruiting
Est. primary completion 2028-01 · NCT05571059 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026Topline resultPhase 2 ASSIST-SSc pilot of ifetroban reports top-line safety results